- Home
- RLYB vs PRLD Comparison
RLYB vs PRLD Comparison
Compare RLYB & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- PRLD
- Stock Information
- Founded
- RLYB 2018
- PRLD 2016
- Country
- RLYB United States
- PRLD United States
- Employees
- RLYB N/A
- PRLD N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- RLYB Health Care
- PRLD Health Care
- Exchange
- RLYB Nasdaq
- PRLD Nasdaq
- Market Cap
- RLYB 45.2M
- PRLD 53.4M
- IPO Year
- RLYB 2021
- PRLD 2020
- Fundamental
- Price
- RLYB $0.92
- PRLD $1.47
- Analyst Decision
- RLYB Buy
- PRLD Strong Buy
- Analyst Count
- RLYB 6
- PRLD 2
- Target Price
- RLYB $8.10
- PRLD $4.50
- AVG Volume (30 Days)
- RLYB 125.7K
- PRLD 733.8K
- Earning Date
- RLYB 11-07-2024
- PRLD 02-13-2025
- Dividend Yield
- RLYB N/A
- PRLD N/A
- EPS Growth
- RLYB N/A
- PRLD N/A
- EPS
- RLYB N/A
- PRLD N/A
- Revenue
- RLYB $598,000.00
- PRLD $3,000,000.00
- Revenue This Year
- RLYB N/A
- PRLD N/A
- Revenue Next Year
- RLYB N/A
- PRLD N/A
- P/E Ratio
- RLYB N/A
- PRLD N/A
- Revenue Growth
- RLYB N/A
- PRLD N/A
- 52 Week Low
- RLYB $0.84
- PRLD $0.80
- 52 Week High
- RLYB $3.46
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- RLYB 39.33
- PRLD 66.82
- Support Level
- RLYB $0.84
- PRLD $1.14
- Resistance Level
- RLYB $1.24
- PRLD $1.59
- Average True Range (ATR)
- RLYB 0.08
- PRLD 0.17
- MACD
- RLYB -0.02
- PRLD 0.08
- Stochastic Oscillator
- RLYB 20.30
- PRLD 84.87
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.